Your browser is no longer supported. Please, upgrade your browser.
Settings
KROS [NASD]
Keros Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own0.30% Shs Outstand20.18M Perf Week-10.46%
Market Cap1.28B Forward P/E- EPS next Y-2.54 Insider Trans119.67% Shs Float18.31M Perf Month1.98%
Income-37.30M PEG- EPS next Q-0.57 Inst Own90.10% Short Float3.77% Perf Quarter-20.81%
Sales2.50M P/S512.10 EPS this Y-824.00% Inst Trans28.34% Short Ratio4.51 Perf Half Y4.77%
Book/sh6.48 P/B9.05 EPS next Y38.60% ROA- Target Price86.25 Perf Year-
Cash/sh6.13 P/C9.57 EPS next 5Y- ROE- 52W Range19.10 - 88.80 Perf YTD-16.90%
Dividend- P/FCF- EPS past 5Y- ROI73.40% 52W High-33.99% Beta-
Dividend %- Quick Ratio20.00 Sales past 5Y- Gross Margin- 52W Low206.91% ATR5.48
Employees32 Current Ratio20.00 Sales Q/Q- Oper. Margin- RSI (14)42.85 Volatility10.75% 9.23%
OptionableNo Debt/Eq0.00 EPS Q/Q65.10% Profit Margin- Rel Volume0.71 Prev Close55.25
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume153.33K Price58.62
Recom1.50 SMA20-7.86% SMA50-12.19% SMA20013.64% Volume113,380 Change6.10%
Dec-08-20Reiterated H.C. Wainwright Buy $50 → $100
May-04-20Initiated SVB Leerink Outperform $42
May-04-20Initiated Piper Sandler Overweight $35
May-04-20Initiated Jefferies Buy $37
May-04-20Initiated H.C. Wainwright Buy $50
Mar-05-21 08:00AM  
Mar-02-21 08:00AM  
Feb-17-21 08:00AM  
Jan-25-21 02:45AM  
Dec-21-20 08:00AM  
Dec-17-20 08:00AM  
Dec-09-20 03:44PM  
Dec-08-20 04:03PM  
Dec-07-20 08:00AM  
Nov-17-20 04:01PM  
Nov-16-20 08:00AM  
Nov-12-20 10:11PM  
Nov-10-20 05:12PM  
04:17PM  
Nov-09-20 08:00AM  
Nov-04-20 04:01PM  
Oct-27-20 08:35AM  
Oct-20-20 08:00AM  
Sep-14-20 07:01AM  
Sep-11-20 04:01PM  
Aug-13-20 07:00AM  
Aug-10-20 08:00AM  
Aug-04-20 08:00AM  
Jul-29-20 10:12AM  
Jun-26-20 07:01AM  
Jun-24-20 08:34AM  
Jun-12-20 07:01AM  
May-28-20 07:01AM  
May-22-20 07:00AM  
May-14-20 09:15AM  
May-05-20 11:46AM  
Apr-13-20 04:01PM  
Apr-07-20 08:45PM  
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Knowles JuliusDirectorMar 04Sale55.4811,632645,385420,825Mar 05 07:44 PM
Knowles JuliusDirectorMar 03Sale57.3612,327707,115425,417Mar 05 07:44 PM
Knowles JuliusDirectorMar 02Sale58.7510,711629,285430,283Mar 03 08:40 PM
Knowles JuliusDirectorMar 01Sale63.0912,979818,793434,511Mar 03 08:40 PM
Lachey JenniferChief Scientific OfficerFeb 26Option Exercise0.1133,2003,65261,191Mar 01 04:54 PM
Knowles JuliusDirectorFeb 18Sale63.112,944185,785439,634Feb 18 06:46 PM
Knowles JuliusDirectorFeb 17Sale61.0516,061980,588440,796Feb 18 06:46 PM
Knowles JuliusDirectorFeb 16Sale59.899,612575,671447,136Feb 18 06:46 PM
Knowles JuliusDirectorFeb 12Sale61.537,468459,495450,930Feb 16 05:50 PM
Lachey JenniferChief Scientific OfficerFeb 11Option Exercise0.305,3001,59033,291Feb 16 05:47 PM
Ordonez ClaudiaChief Medical OfficerFeb 11Option Exercise0.481,0004801,000Feb 16 05:49 PM
Knowles JuliusDirectorFeb 11Sale64.8211,561749,441453,878Feb 16 05:50 PM
Ordonez ClaudiaChief Medical OfficerFeb 11Sale64.841,00064,8410Feb 16 05:49 PM
Lachey JenniferChief Scientific OfficerFeb 11Sale64.915,300344,01727,991Feb 16 05:47 PM
Nussbaum RanDirectorNov 17Buy50.0060,0003,000,0002,288,151Nov 19 04:40 PM
Kariv TomerDirectorNov 17Buy50.0060,0003,000,0002,288,151Nov 19 04:39 PM
Pontifax Management 4 G.P. (2010% OwnerNov 17Buy50.0060,0003,000,0002,288,151Nov 19 04:38 PM